

# BEFORE IT'S TOO LATE!

Before patients must go to dialysis, we can improve their health and quality of life.



## FLB RENAL INSTITUTIONAL FOUNDATION

### Unfulfilled Needs

- Prevent kidney disease
- Prolong kidney life
- Improve quality of life for patients
- Increase health-span
- RPM: Remote Patient Monitoring 24/7 and 47 points of baseline testing
- Maintain a healthy immune system (key to longevity)
- Give access to multiple types of cell therapies, derivatives and innovative care
- Help delay or avoid dialysis treatments, hospitalization and hospice care
- Build a holistic campus with senior living, assisted living, nursing home and hospice care
- Facilitate the last stressful transitions in patients' life
- Include on the campus, a dialysis center and a full medical laboratory

- Older Population = More Kidney Disease
- 130 million hypertensive diabetics
- 700,000 dialysis patients in USA
- 31 million CKD patients
- \$28 Billion spent for dialysis in 2020
- Since 1974, Medicare reimbursed bi-weeks on a basis of net 40% gross profit.
- CKD is becoming more prevalent and will consume a significant portion of the Medicare budget.

### Our Solutions

- The FLB Group owns dialysis units
- 12 ambulatory surgery centers using FLB mobile service
- 10 years of personnel and relationships to capture a portion of the medical market
- Can expand across the US, with a growth factor of 6% per year
- Planned investigational new drug (IND) application to the federal drug administration (FDA) in order to eventually receive a biological license

#### Can you introduce us to:

- Senior and assisted living facilities
- Nursing homes and hospices
- Medical clinics and doctors
- Diabetics and hypertensive patients or anyone at risk of kidney diseases
- Decision makers and investors in different Cities and Counties

### REGENERATIVE & PREVENTIVE MEDICINE



818.914.9152



chuck@flbdialysis.com



www.flbRegenesis.com

## Our Team

### Nadine Lajoie, B.Sc. (Actuarial Sciences):

International award-winning business woman, in finances and business for over 33 years, TEDx and International Leadership Speaker, #1 Best-Selling Author featured on Forbes, USA Today, Fox News and more.



Dr. Paul Rosbury: Chairman and Spiritual Director of Seminary Covenant Community, a Group 501(c)3 Ministry Membership Organization, with 35 years of experience as an advisor to non-profit, faith-based organizations and churches.

Chuck de La Mater, BS, MBS: Dialysis patient for over 18 years, Founder and Chairman of FLB ReGenesis, LLC and affiliated companies, helping dialysis and CKD communities with regenerative medicine, product line, and treatments for patients.



Jim Brown, Director: Involved with FLB since the inception, helping with investor relations and financial aspects. Owner of Keller Williams Corona, Jim has been involved in real estate for over 30 years, including land development, residential, short sales and bank-owned properties.

Chuck started First Learn Balance (FLB) over 10 years ago because he was dissatisfied with how the industry treated him and other patients, and he set out to develop better solutions!



### **Cellular Therapy Market:**

- Global stem cell market was \$55 million in 2018 and is expected to reach \$11 billion US by 2029.
- Regenerative medicine is an interdisciplinary approach that involves repairing or replacing damaged tissues or organs.
- All testing is done under an approved Medicare doctor and billed directly to Medicare.

### Valiant Naona, Director:

27 years manufacturing engineering and design experience; Val has been involved since 2011 in the development of chronic kidney awareness and related projects to benefit dialysis patients. Val is a part-owner of FLB ReGenesis and has played a vital role in the development and success of FLB.

### **CONTACT US NOW**

The FLB Foundation aims to give back to the community and help individuals who are at risk of kidney disease.



818.914.9152



chuck@flbdialysis.com



www.flbRegenesis.com



## **Executive Summary**

---

### ***Overview***

FLB Renal Institutional Foundation ("The Foundation") is operating under the 501(c)3 regulations and is the non-profit side of FLB ReGenesis, LLC, a management Services Company, FLB (First Learn Balance) and their affiliated companies ("The FLB Group") related to recruitment, management of health care services, research and development of regenerative methods of prolonging kidney's life.

### ***Mission***

FLB Renal Institutional Foundation will provide free and low-cost services for patients to have access to the proactive medical solutions through 24/7 remote patient monitoring (RPM), while increasing health-span and prolonging the quality of life for patients with kidney disease. The Foundation will also give access to multiple types of cell therapies, derivatives and innovative care to serve an unmet need to the vast medical community.

### ***Vision***

Our vision at FLB Renal Institutional Foundation is to become the #1 company in the USA for preventive care, regenerative treatments and innovative cell platform in the kidney disease community, before the patients have to go to dialysis, so we can improve their health and quality of life, before it is too late!

### ***Goals***

Our goals are to prevent kidney diseases, prolong kidney's life and improve the quality of life for patients with kidney diseases or CKD (Chronic Kidney Disease). Monitoring patients with the RPM system 24/7 will help delay or avoid, as long as possible, dialysis treatments, hospitalization and hospice care.

The dialysis community consists of 700,000 dialysis patients in the USA, as well as 31 million chronic kidney disease patients and 130 million hypertensive diabetics in danger of contracting kidney failure.

### ***Current Market:***

The market to prevent kidney disease is completely underserved, because prevention and innovative treatments are pretty much non-existent and not a priority in our health care system.

According to the CDC, the United States has 130 million hypertensive diabetic patients, with 31 million of those patients who have developed CKD. There are presently 700,000 dialysis patients in our Country and growing at an alarming rate. The Foundation is collaborating with the FLB Group, who owns their own dialysis

units, that will enable us the ability to expand these same ideals across the US, with a growth factor of 6% per year.

Since 1974, Medicare has reimbursed every 2 weeks on a basis of net 40% gross profit. Year ending 2020 direct related dialysis cost to Medicare exceeded 28 billion dollars. The previous amount does not include co-morbidities caused by kidney disease and related fees paid to hospitals and other providers. In short, CKD is at an epidemic of massive proportion and will be overtaking major consumption of the Medicare budget.

Some companies in the FLB Group have been up and running for the past 8 years, and for 6 years, using stomal vascular fraction isolated from fat tissue as a regenerative medicine tool. We have accumulated 12 ambulatory surgery centers using our mobile service, which trains our associated doctors in the procedure that treats a number of morbidities in which our focus will be in the CKD arena with a planned investigational new drug (IND) application to the federal drug administration (FDA) in order to eventually receive a biological license's for marketing through ownership with FLB's collaborative agreements set with Med Edge medical, The Bio Box, Cord for Life, and Peak wellness.

### **Cellular Therapy Market:**

Biologics are of immense importance for the future of medicine and anti-aging. Cells are the fundamental structural and functional units of all living things. They are the smallest unit of life and often referred to as the building block of life because all organisms are composed of at least one cell. All cells come from existing cells and all life functions occur within cells that contain the hereditary information necessary for regulating cell function.

Cell replacement therapy and stem cell therapy have been used for over 40 years. Autologous stem cells (cells from your own body) and allogeneic cells (from another source) have successfully treated diseases for many years. Current projections indicate that cellular therapy will continue to grow exponentially as baby boomers age and are looking for alternative treatment options to maintain their health and improve quality of life.

According to BIS Research, the global stem cell market was \$55 million in 2018 and is expected to reach \$11 billion US by 2029. The same report estimates CAGR of 27.99% during the forecast period from 2019 to 2024

The increase of an older population has shown an increase in the prevalence of chronic disease, which has led to a greater demand to treat the disease and not the symptoms, hence being proactive in our approach. Regenerative medicine is an interdisciplinary approach that involves repair or replacement of damaged tissues or organs to cure disease.

Stem cells, a sub-segment of cellular therapy, represent the centerpiece of regenerative medicine. The rising awareness and proven potential of stem cells and stem cell products are the driving factors within the global stem cell market.

### **Adaptive Cell Transfer**

Maintaining a healthy immune system is key to longevity. Our immune system is challenged daily with foreign attacks and invaders. The problem is, as we age so does our immune system. By the time you hit 40-80 years of age you have a 50% chance of getting cancer.

Natural killer (NK) cells are one of our first lines of defense against cancer, viruses and aging cells (senescence). NK cells are presently used in greater than 750 clinical trials for cancer. They have shown much

promise in killing and possibly curing cancer. They work by boosting your immune system to target the cancer and directly targeting the cancer themselves. The problem is, they also age as we age and do not target and attack like they did when they were young. NK cell activation has shown much promise in the cancer segment and maintains a youthful immune system. Moreover, studies have illustrated that NK cells can wipe out senescence forcing the body to regenerate to a younger state.

T cells are white blood cells that play a central role in the immune response and are at the core of adaptive immunity. They are like soldiers that seek out and destroy invaders. However, in some instances they can go awry or not target effectively. In some instances, they can even target our own body for destruction, as is the case in autoimmune disease.

Regulatory T cells (T-regs) are a subtype of T cell that are essential in maintaining the T cell response in our body. As we age, their capability diminishes substantially and they do not regulate immune responses correctly. Studies in autoimmune diseases have illustrated that if T-regs are increased, disease is modified and improved significantly.

### **Technology and Products:**

We currently use stem cells for treating several diseases such as cardiovascular disease, spinal cord injury, arthritis, ALS, pulmonary disease, frailty (anti-aging), autoimmune disease and sports injuries. These therapies currently take place at our facilities all over the world.

In addition, we have partnered with innovative care, a remote patient monitoring system (RPM) as a 50% owner in the data collection on our patients taking part in our clinical trials. This data over time will be generated into artificial intelligence in the diagnosis of patient morbidities. They accomplish this task by a 24/7 tracking of patient vitals and 47 points of baseline testing, as well as the same testing after cellular treatments at 30 days, 90 days, 180 days and one year. All testing is done under an approved Medicare doctor and billed directly to Medicare, so there is no additional cost. We have added this data to the platform created by innovative care.

This group has come together over the last 8 years and now has accumulated the personnel and relationships to enable this organization to capture a portion of the medical market, which at this time is left unfulfilled.

The Foundation is the needed progression to be able to give back to the community, promote and help anyone who are at risk of kidney disease, by using all this amazing work performed by the FLB Group and accessing their new technologies, treatments and solutions available at this moment and in the future.

### **Team**

**Nadine Lajoie, President, B.SC. (Actuarial Sciences):** International Speaker and Award-Winning Business Woman (23 awards), in business and finances (Can-USA) for over 33 years, Nadine will lead, promote and manage our non-profit organization that will provide the RPM equipment to patients and inspire them to achieve their healthier goals.

She was featured on Forbes, USA Today, ABC, FOX and CBS Money Watch, became a #1 Best-Selling Author and an International Speaker on TEDx, California Women's Conference and major stages around the world, along with Tom Hopkins, John Gray, Mark Victor Hansen, Jamie Lee Curtis, Les Brown, Marianne Williamson, Michael Beckwith, etc.

**Paul Rosbury, Vice-President:** Dr. Paul Rosbury is Chairman and Spiritual Director of Seminary Covenant Community, a Group 501(c)3 Ministry Membership Organization that also includes FLB Renal Institutional Foundation. He is a Pastor, Teacher, Coach, and Advisor to build organization's leadership, establish non-profit and faith-based organizations for 35 years, as well as churches, educational, social and humanitarian organizations. He is known as the "Solutions Man".

He created a 5X5 Business Acceleration Matrix covering 25 modules, formed and executed a multitude of ministries, including revivals and outreach programs, and developed 2 life changing restoration for managed behaviors and recovery programs for substance abuse, known as CLIMB and ADAPT.

**Chuck de La Mater, Director:** BS, MBS, industrial hygienist MBS, Advisory board member and holding FLB ReGenesis, LLC company board chair. Chuck has been a dialysis patient for 16 years and is the founder of the FLB Group for the dialysis and CKD communities. Chuck's role within this structure will act in the capacity of an operating manager of patient recruitment and management thereof, as well as delivery systems for its product lines.

**Jim Brown, Director:** Involved with FLB since the inception, Jim is helping with investor relations and financial aspects. Owner of Keller Williams Corona, Jim has been involved in real estate for over 30 years, including land development, residential, short sales and bank-owned properties. Graduated from the University of Southern California, Michael worked in the Entertainment Industry in Game Shows, VP Film Acquisitions, and Producer. He is also a Real Estate Developer and Specialized as a Historical Restoration Investor.

**Valiant Naona, Director:** 27 years manufacturing engineering and design experience; Roll Right Industries, Janus International and VP/partner Epic Doors Inc. Coming out of retirement in 2011, Val has been involved in the development of chronic kidney awareness and related projects to benefit dialysis patients. Val has been instrumental in the development of FLB ReGenesis and is presently serving on the Five Member Management Committee and will serve in the Business Development functions of the company. As a part owner of FLB ReGenesis, he will be instrumental in its development and success.



## Schedule of Values

Description	Value	Months	Each	Hours	Patients	TOTAL
Principal Investigator (Dr. Kevin Tehrani)	\$800				180	\$144,000
Clinical Director/FDA Compliance (Dr. Gonzalz)	\$500			832		\$416,000
Summit Surgery – Adipose	\$3,500				40	\$140,000
- Xosomes	\$1,500				40	\$60,000
- Pure mezcymal	\$1,500				40	\$60,000
- Adipose derive regenerative tissue	\$1,500				40	\$60,000
FLB MobilCell - regenerative mobil services	\$4,100				40	\$164,000
Niana Shevgiv, Functional Medicine, peak state	\$8,500				100	\$850,000
The BIO Box - cord blood products (3 cc)	\$3,900				40	\$156,000
The BIO Box, Restem w/ alsian-Re-stem Exosomes (10cc's)	\$1,500				40	\$60,000
BioStem Technologies - xosomes	\$500				40	\$20,000
- Dr. Rafiel Gonzalez (2cc)	\$2,600				40	\$104,000
research assistant/ Lab Core	\$65,000		2			\$130,000
medical attorney fees	\$10,000	24				\$240,000
Corp taxes/fees	\$10,000		1			\$10,000
Dr. Maxey - White paper	\$140,000		1			\$140,000
- CKD patient clearance fee	\$500				180	\$90,000
- associated doctors advertising	\$250				180	\$45,000
					<b>Sub Total</b>	<b>\$2,889,000</b>

<b>FLBRG Mgmt Fee</b>						
Dr. Rafael Gonzalez- Director of Operations (CMC's)	\$15,000	24				\$360,000
Chuck De La Mater - Patient Recruitment	\$10,000	24				\$240,000
Nadine's Group	\$10,000	24				\$240,000
Contingency 5%						\$357,550
<b>Salaried Advisory Board</b>						
Dr. Bruce Werber - BioStem Technologies	\$3,500	24				\$84,000
Jeff Granier - Healeon Medical	\$3,500	24				\$84,000
Corepath Diagnostics, LLC	\$3,500	24				\$84,000
					<b>Sub Total</b>	<b>\$1,449,550</b>
Contingency	\$25,000	24				\$300,000
					<b>TOTAL</b>	<b>\$4,638,550</b>